scholarly article | Q13442814 |
P356 | DOI | 10.2967/JNUMED.114.141887 |
P8608 | Fatcat ID | release_o4k6sblyifdvresx4jjs3m7ay4 |
P698 | PubMed publication ID | 25552670 |
P5875 | ResearchGate publication ID | 270289148 |
P50 | author | Laura Evangelista | Q52983502 |
Anna Rita Cervino | Q53065838 | ||
Duccio Volterrani | Q59660510 | ||
Eugenio Borsatti | Q84071666 | ||
Giulia Puccini | Q114332164 | ||
P2093 | author name string | Giuliano Mariani | |
Jure Fettich | |||
Marina Hodolič | |||
Giorgio Saladini | |||
Marino Cimitan | |||
Michele Gregianin | |||
Federica Guidoccio | |||
Tanja Baseric | |||
Valentina Bodanza | |||
P433 | issue | 2 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 209-215 | |
P577 | publication date | 2014-12-31 | |
P1433 | published in | The Journal of Nuclear Medicine | Q7743608 |
P1476 | title | Gleason score at diagnosis predicts the rate of detection of 18F-choline PET/CT performed when biochemical evidence indicates recurrence of prostate cancer: experience with 1,000 patients | |
P478 | volume | 56 |
Q90721180 | 18F-Choline PET/CT Identifies High-Grade Prostate Cancer Lesions Expressing Bone Biomarkers |
Q92128120 | 18F-fluciclovine PET CT detection of biochemical recurrent prostate cancer at specific PSA thresholds after definitive treatment |
Q50099352 | 18F-fluorocholine PET/CT in patients with occult biochemical recurrence of prostate cancer: Detection rate, impact on management and adequacy of impact. A prospective multicentre study |
Q52983532 | A pilot study of the utility of choline PET-CT in prostate cancer biochemical relapse following radical prostatectomy. |
Q38833159 | Acquisition with (11)C-choline and (18)F-fluorocholine PET/CT for patients with biochemical recurrence of prostate cancer: a systematic review and meta-analysis |
Q44453209 | Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer |
Q52984262 | Detection of recurrent prostate cancer lesions before salvage lymphadenectomy is more accurate with (68)Ga-PSMA-HBED-CC than with (18)F-Fluoroethylcholine PET/CT. |
Q50721465 | Diagnosis of recurrent prostate cancer with PET/CT imaging using the gastrin-releasing peptide receptor antagonist 68Ga-RM2: Preliminary results in patients with negative or inconclusive [18F]Fluoroethylcholine-PET/CT. |
Q42257970 | Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-Ligand-PET/CT before Salvage Lymph Node Dissection for Recurrent Prostate Cancer |
Q38766102 | Diagnostic imaging to detect and evaluate response to therapy in bone metastases from prostate cancer: current modalities and new horizons. |
Q47965751 | Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score |
Q89823517 | Imaging for Metastasis in Prostate Cancer: A Review of the Literature |
Q56358992 | Imaging of Prostate Cancer Using Fluciclovine |
Q41829682 | Initial single-centre Canadian experience with 18F-fluoromethylcholine positron emission tomography-computed tomography (18F-FCH PET/CT) for biochemical recurrence in prostate cancer patients initially treated with curative intent |
Q52411549 | Molecular imaging of prostate cancer. |
Q52982373 | No clinically relevant differences between positron emission tomography (PET) reconstructions based on low-dose or contrast-enhanced CT in combined integrated multiphase (18) F-Fluorethylcholine PET/CT for prostate cancer. |
Q55395878 | Optimization of temporal sampling for 18F-choline uptake quantification in prostate cancer assessment. |
Q39242140 | PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies |
Q39003089 | PSMA PET and Radionuclide Therapy in Prostate Cancer |
Q57110351 | Positron emission tomography in prostate cancer: An update on state of the art |
Q37427275 | Predictive factors of 18F-choline PET/CT positivity in patients with prostate cancer recurrence after radiation therapy: is the impact of PSA nadir underestimated? |
Q90387663 | Prostate cancer imaging: when the game gets tough, the hard one gets done! |
Q34522627 | Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT. |
Q49908509 | The relationship between local recurrences and distant metastases in prostate cancer: can 11C-choline PET/CT contribute to understand the link? |
Q33625389 | Update on advances in molecular PET in urological oncology |
Search more.